PTO/SB/21 (01-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Pagerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/613,782 TRANSMITTAL Filing Date July 3, 2003 FORM First Named Inventor Mattei et al Art Unit (to be used for all correspondence after initial filing) **Examiner Name** Attorney Docket Number 21159 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to Group Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Identify below): Extension of Time Request Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Cited art Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Eileen M. Ebel Individual Signature

CERTIFICATE OF TRANSMISSION/MAILING								
	rrespondence is being transmitted to the USPTO or deposited with the Unitessed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313							
Typed or printed	Eileen M. Ebel							
Signature	Enler by a Ca	Date January 8, 2004						

Date

January 8, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



### PATENT APPLICATION

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Mattei et al

Group:

Serial No. 10/613,782, filed July 3, 2003

Examiner:

For:

**QUINAZOLINE DERIVATIVES** 

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 January 8, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Document B12 -B15 listed on Form PTO-1449 are enclosed. Document A8 is cited.

Enclosed is a Search Report, dated October 13, 2003, which was issued by the European Patent Office in PCT/EP 03/06868 application corresponding to the captioned application. The Search Report lists Documents B12-B15.

Document B15 corresponds to Document A8, U.S. Patent No. 3,753,981, which is not being submitted because it is a U.S. Patent. Document B12, which is in Japanese, includes an English language abstract.

Serial No. 10/613,782

Filed: July 3, 2003

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before receipt of the first Office Action on the merits and because each item of information contained in the Information Disclosure Statement was cited in a communication for the first time from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, no fee is due. A Certification is enclosed.

Respectfully submitted,

Attorney for Applicant(s)

Eileen M. Ebel (Reg. No. 37316) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-4391

136520

ابير الله		Substitute for form 1449A/PTO		Comple	Complete if Known			
<b>≥</b> 1								
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	Application Number 10/613,7				
			First Name Inventor		July 3, 2003			
	(Use several sheets if necessary)			Group Art Unit				
	(00000	······································		Examiner Name	<u> </u>			
Ch-st 1	<u>.                                    </u>	1 of 1		Attorney Docket Number	21159			
Sheet 1	<u> </u>	of 1	*** C *** ***	<u> </u>	21139			
	ı	II C. Datant Do		ENT DOCUMENTS		1		
Examiner	U.S. Patent Document		Name of Patentee or Applicant of		f Date of Publication of			
Initials'	No.'	Number Kind Code <sup>2</sup> (if known)		Cited Document		Cited document		
						MM-DD-YYYY		
*	A8	3,753,981		Hermann Breuer et al	l	08-21-1973		
	<del>                                     </del>							
				<u> </u>				
		·						
					-			
<u>.</u>								
						_		
		I	OREIGN P	PATENT DOCUMENTS				
		Foreign Patent Document				Date of Publication of T		
Examiner	Cite No.1	Office <sup>3</sup> Number Kind Cod		Name of Patentee or		Cited Document		
Initials'		Office Number	(if known)	Applicant of Cited Docum		<del></del>		
	B12	WO 99 09986		Kyowa Hakko	03-	03-04-1999		
	B13	EP 0 669 324		Eisai	08-30-1995			
	B14	WO 92 07844		Pfizer	05-	05-14-1992		
				Squibb & Sons		03-24-1972		
	B15	FR 2 100 916		Squiou & Solis	100 & 30115 03		+-	
							+-	
							<u> </u>	
	<del>                                     </del>							
							-	
	ļ						<u> </u>	
Examiner Signature		Date Considered						

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Unique citation designation number. \*See attached Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation or abstract is attached.

#### PATENT APPLICATION



In re Patent Application

Inventors: Mattei et al.

Group:

Serial No. 10/613,782, filed July 3, 2003

Examiner:

For: QUINAZOLINE DERIVATIVES

## **STATEMENT UNDER 37 CFR §1.97(e)**

Nutley, New Jersey 07110 Date: January 8, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify:

X That each item of information contained in the enclosed information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this information disclosure statement.

That <u>no</u> item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Attorney for Applicant(s)

Eileen M. Ebel (Reg. No. 37316)

340 Kingsland Street

Nutley, NJ 07110

Telephone: (973) 235-4391 Telefax: (973) 235-2363